ES2117797T3 - Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina. - Google Patents

Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina.

Info

Publication number
ES2117797T3
ES2117797T3 ES94924368T ES94924368T ES2117797T3 ES 2117797 T3 ES2117797 T3 ES 2117797T3 ES 94924368 T ES94924368 T ES 94924368T ES 94924368 T ES94924368 T ES 94924368T ES 2117797 T3 ES2117797 T3 ES 2117797T3
Authority
ES
Spain
Prior art keywords
sup
sub
gastrine
cck
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94924368T
Other languages
English (en)
Inventor
Graeme Semple
Hamish Ryder
Michael Szelke
Masato Satoh
Mitsuaki Ohta
Keiji Miyata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Ferring BV
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd, Ferring BV filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2117797T3 publication Critical patent/ES2117797T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Lubricants (AREA)

Abstract

UN DERIVADO DE LA FORMULA (I), O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE: (A) R{SUP,4} ES UN GRUPO ALQUILO, CICLOALQUILO O ARILO; (B) R{SUP,10} SE SELECCIONA DEL HALO, OH, CH{SUB,3}, OCH{SUB,3}, NR{SUP,11}R{SUP,12}, NO{SUB,2}, NHCHO, CO{SUB,2}H Y CN Y R{SUP,11} Y R{SUP,12} SE SELECCIONAN INDEPENDIENTEMENTE DEL H Y ALQUILO (C{SUB,1}-C{SUB,5}) O JUNTO CON NR{SUP,11}R{SUP,12} FORMAN UNA ESTRUCTURA CICLICA (II), EN LA QUE A ES DE 1 A 6; Y (C) R{SUP,2} ES UN HETEROCICLO SUSTITUIDO O NO SUSTITUIDO, DE 5 O 6 ELEMENTOS, AROMATICO, QUE CONTIENE AL MENOS DOS HETEROATOMOS DE LOS CUALES AL MENOS UNO ES NITROGENO. ESTOS COMPUESTOS SON ANTAGONISTAS DE LA GASTRINA Y/O DEL RECEPTOR CCK-B.
ES94924368T 1993-08-25 1994-08-25 Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina. Expired - Lifetime ES2117797T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9317693A GB2282595A (en) 1993-08-25 1993-08-25 Benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
ES2117797T3 true ES2117797T3 (es) 1998-08-16

Family

ID=10741026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94924368T Expired - Lifetime ES2117797T3 (es) 1993-08-25 1994-08-25 Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina.

Country Status (21)

Country Link
US (1) US5728829A (es)
EP (1) EP0715624B1 (es)
JP (1) JPH09504005A (es)
KR (1) KR960703873A (es)
CN (1) CN1129442A (es)
AT (1) ATE164840T1 (es)
AU (1) AU687433B2 (es)
CA (1) CA2169089A1 (es)
CZ (1) CZ53096A3 (es)
DE (1) DE69409534T2 (es)
DK (1) DK0715624T3 (es)
ES (1) ES2117797T3 (es)
FI (1) FI960836A7 (es)
GB (1) GB2282595A (es)
HU (1) HUT73978A (es)
IL (1) IL110783A0 (es)
NO (1) NO960747L (es)
NZ (1) NZ271131A (es)
PL (1) PL313165A1 (es)
WO (1) WO1995006040A1 (es)
ZA (1) ZA946474B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2215242T3 (es) 1996-11-19 2004-10-01 Amgen Inc. Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
CA2274669C (en) * 1996-12-10 2006-11-14 Zeria Pharmaceutical Co., Ltd. 1,5-benzodiazepine derivatives
FR2782997A1 (fr) * 1998-09-08 2000-03-10 Hoechst Marion Roussel Inc Nouveaux derives de la benzodiazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicaments et compositions pharmaceutiques les renfermant
JPWO2002092096A1 (ja) * 2001-05-11 2004-08-26 山之内製薬株式会社 抗腫瘍剤
GB0221923D0 (en) * 2002-09-20 2002-10-30 Arrow Therapeutics Ltd Chemical compounds
US7196079B2 (en) * 2003-06-26 2007-03-27 Merck & Co, Inc. Benzodiazepine CGRP receptor antagonists
JP5197361B2 (ja) * 2005-06-06 2013-05-15 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 睡眠障害を処置するための組成物および方法
KR102254957B1 (ko) 2013-11-22 2021-05-25 씨엘 바이오사이언시즈 엘엘씨 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드)
GB201414116D0 (en) * 2014-08-08 2014-09-24 Trio Medicines Ltd Benzodiazepine derivatives
GB201513979D0 (en) 2015-08-07 2015-09-23 Trio Medicines Ltd Synthesis of benzodiazepine derivatives
US10881667B2 (en) 2018-10-30 2021-01-05 City University Of Hong Kong Method and composition for treating epilepsy
CN109553591B (zh) * 2019-01-15 2020-12-15 山东安信制药有限公司 一种富马酸喹硫平中间体的制备方法
US11285161B2 (en) 2019-04-26 2022-03-29 City University Of Hong Kong Method and composition for treating mental disorder and pain associated with nerve damage
FR3097222B1 (fr) * 2019-06-11 2021-05-28 Michelin & Cie Nouveaux composes 1,3-dipolaires comprenant un heterocycle aromatique et un cycle imidazole
WO2025122363A2 (en) * 2023-12-07 2025-06-12 Evergreen Discovery, LLC Methods of treating small cell lung cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
IL96613A0 (en) * 1989-12-18 1991-09-16 Merck & Co Inc Pharmaceutical compositions containing benzodiazepine analogs
JPH07119217B2 (ja) * 1990-12-25 1995-12-20 山之内製薬株式会社 新規ベンゾジアゼピン誘導体
GB9116113D0 (en) * 1991-07-25 1991-09-11 Merck Sharp & Dohme Therapeutic agents
FR2682381B1 (fr) * 1991-10-10 1995-04-07 Rhone Poulenc Rorer Sa Derives de benzodiazepine, leur preparation et les medicaments les contenant.
WO1993007131A1 (en) * 1991-10-10 1993-04-15 Merck Sharp & Dohme Limited Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors
EP0538945A1 (en) * 1991-10-24 1993-04-28 Glaxo Group Limited Benzodiazepine derivatives, and their use as antagonists of gastrin and/or cholecystokinin
IL104853A (en) * 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
GB2264492B (en) * 1992-02-27 1996-09-25 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
CA2138129A1 (en) * 1992-06-24 1994-01-06 Masato Satoh Novel benzodiazepine derivative

Also Published As

Publication number Publication date
WO1995006040A1 (en) 1995-03-02
NO960747D0 (no) 1996-02-23
FI960836A0 (fi) 1996-02-23
US5728829A (en) 1998-03-17
HUT73978A (en) 1996-10-28
HU9600205D0 (en) 1996-04-29
KR960703873A (ko) 1996-08-31
PL313165A1 (en) 1996-06-10
ZA946474B (en) 1996-03-25
CA2169089A1 (en) 1995-03-02
CN1129442A (zh) 1996-08-21
CZ53096A3 (en) 1996-09-11
NO960747L (no) 1996-04-25
DK0715624T3 (da) 1999-01-11
AU7466194A (en) 1995-03-21
FI960836A7 (fi) 1996-04-22
EP0715624A1 (en) 1996-06-12
GB9317693D0 (en) 1993-10-13
AU687433B2 (en) 1998-02-26
DE69409534D1 (de) 1998-05-14
JPH09504005A (ja) 1997-04-22
ATE164840T1 (de) 1998-04-15
NZ271131A (en) 1997-11-24
DE69409534T2 (de) 1998-08-06
GB2282595A (en) 1995-04-12
IL110783A0 (en) 1994-11-11
EP0715624B1 (en) 1998-04-08

Similar Documents

Publication Publication Date Title
ES2117797T3 (es) Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina.
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
ES8603801A1 (es) Un metodo para preparar derivados de alcanoles aromaticos policiclicos
ES2150918T3 (es) 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas.
ES2121760T3 (es) Compuesto de pirazolopiridina y procedimiento para su preparacion.
ES2113656T3 (es) Pirazolopirimidinonas para el tratamiento de la impotencia.
HU907660D0 (en) Process for producing tricyclic compounds and pharmaceutical preparatives containing such compounds as active substances
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
ES2196344T3 (es) Derivados de sulfonamida y su uso en el tratamiento de trastornos de snc.
ES2113368T3 (es) Antagonistas de serotonina.
MX9201356A (es) Derivados de piperidina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
UY24482A1 (es) Quinoxalinadionas
ES2095976T3 (es) Compuestos de pirazolopiridina y procedimiento para su preparacion.
MX9207335A (es) Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene.
DE69434888D1 (de) 5-ht4-rezeptor-antagonisten
DK620784A (da) Nye tricykliske aminer
ES2104841T3 (es) Fosfono-aminoacidos bencimidazolicos.
MX9307946A (es) Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso.
ES2123560T3 (es) Composiciones farmaceuticas que comprenden derivados de hidroxamato para la eliminacion del hierro.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2140181T3 (es) Androstenonas.
MX9301045A (es) Procedimiento para preparar antagonistas receptores de fibrinogeno.
ES2171646T3 (es) Uso de derivados de vinpocetina para la inhibicion o produccion de beta-proteina amiloide.
ES2091283T3 (es) Derivados de isocromano.
ES2131300T3 (es) Derivados triciclicos y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 715624

Country of ref document: ES